These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38774490)

  • 1. Five-alpha reductase inhibitors and risk of prostate cancer among men with benign prostatic hyperplasia: A historical cohort study using primary care data.
    Thakrar DB; Douglas IJ; Smeeth L; Bhaskaran K
    Wellcome Open Res; 2023; 8():295. PubMed ID: 38774490
    [No Abstract]   [Full Text] [Related]  

  • 2. The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
    Ayodele O; Cabral HJ; McManus D; Jick S
    Clin Epidemiol; 2021; 13():661-673. PubMed ID: 34377032
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia.
    Hagberg KW; Divan HA; Fang SC; Nickel JC; Jick SS
    Clin Epidemiol; 2017; 9():83-91. PubMed ID: 28228662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study.
    Cindolo L; Pirozzi L; Fanizza C; Romero M; Tubaro A; Autorino R; De Nunzio C; Schips L
    Eur Urol; 2015 Sep; 68(3):418-25. PubMed ID: 25465970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery.
    Naslund M; Eaddy MT; Hogue SL; Kruep EJ; Shah MB
    Curr Med Res Opin; 2009 Nov; 25(11):2663-9. PubMed ID: 19757985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
    Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
    JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
    Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
    BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Analysis of Prostate Cancer Development Following Five-alpha Reductase Inhibitor Treatment for Benign Prostate Hyperplasia.
    Chang LW; Wang SS; Yang CK; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Li JR
    Anticancer Res; 2023 Jan; 43(1):485-491. PubMed ID: 36585197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular Safety and Possible Benefit of a 5-Alpha Reductase Inhibitor among Benign Prostatic Hyperplasia Patients, A Nationally Representative Cohort of Korean Men.
    Chang J; Choi S; Kim K; Park SM
    J Clin Med; 2019 May; 8(5):. PubMed ID: 31121994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
    Hagberg KW; Divan HA; Nickel JC; Jick SS
    Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
    Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
    J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations.
    Earnshaw SR; McDade CL; Black LK; Bell CF; Kattan MW
    Pharmacoeconomics; 2010; 28(6):489-505. PubMed ID: 20196623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
    Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
    Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic analysis of benign prostatic hyperplasia identifies critical pathways in prostatic overgrowth and 5-alpha reductase inhibitor resistance.
    Jin R; Forbes CM; Miller NL; Lafin J; Strand DW; Case T; Cates JM; Liu Q; Ramirez-Solano M; Mohler JL; Matusik RJ
    Prostate; 2024 Apr; 84(5):441-459. PubMed ID: 38168866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of benign prostatic hyperplasia: Results from a population-based study.
    Bishr M; Boehm K; Trudeau V; Tian Z; Dell'Oglio P; Schiffmann J; Jeldres C; Sun M; Shariat SF; Graefen M; Saad F; Karakiewicz PI
    Can Urol Assoc J; 2016; 10(1-2):55-9. PubMed ID: 26977208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
    Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia.
    Chung JS; Seo WI; Oh CK; Kim SC; Park MC; Park SH; Yu J; Lee CH; Kim W; Park TY; Min KS; Chung JI
    Investig Clin Urol; 2020 Jan; 61(1):67-74. PubMed ID: 31942465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
    DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.